Sesques, P., Houot, R., Tabaa, Y. A., Bras, F. L., Ysebaert, L., Choquet, S., Camus, V., Bay, J., Gros, F., Morschhauser, F., Casasnovas, O., Gastinne, T., Thieblemont, C., Joris, M., Ricard, L., Regny, C., Rochelle, L. D. L., Feugier, P., Marcais, A., Chaillol, I., Tarte, K., Laurent, C., Cartron, G. (2025). Glofitamab is superior to non a-CD3xC20 treatments for patients with diffuse large B-cell lymphoma who are refractory or relapse immediately after anti-CD19 CAR T-cell therapy: Final results of the bicar study (LYSA) and indirect comparison with a synthetic control arm from the descart registry.. Blood. https://doi.org/10.1182/blood-2025-1958